15 results about "Tubular cell" patented technology

The present invention aims to provide a cytoprotective agent against ferroptosis that contains DHMBA as an active ingredient, by verifying the effect of DHMBA in suppressing ferroptotic cell death using DN model mice and human renal tubular cells HK-2, for each useful agent containing DHMBA as an active ingredient. [Solution] The present invention provides a cell agent for ferroptosis that has a cytoprotective effect against ferroptosis, comprising 3,5-dihydroxy-4-methoxybenzyl alcohol as an active ingredient.

The invention discloses an application of a targeted ECT2 inhibitor in preparation of a product for treating renal interstitial fibrosis. According to the application, a brand-new and unprecedented molecular pathway which activates a p53 pathway by inhibiting ribosome biogenesis (RiBi) and finally causes renal tubular cell aging and renal fibrosis is revealed and confirmed for the first time, and a solid theoretical basis is provided for precise drugs aiming at the pathway; and a major breakthrough from relevance observation to causality mechanism clarification is realized.

The invention relates to the technical field of biological medicine, and discloses an activated cis-platinum reversible coordination complex, coordination nano-micelles thereof and application of the activated cis-platinum reversible coordination complex and the coordination nano-micelles. The activated cis-platinum reversible coordination complex is a complex formed by a coordination material and a metal platinum drug or an activated molecule thereof or a derivative thereof, and the coordination ratio of a coordination group in the coordination material to the metal platinum drug or the activated molecule thereof or the derivative thereof is less than or equal to 2: 1; the coordination material is a coordination phospholipid-like material or a coordination polymer material; the metal platinum medicine or the activated molecule or the derivative thereof is cis-platinum, carboplatin, lobaplatin, epithiaplatin, nedaplatin, oxaliplatin or the activated molecule or the derivative thereof. According to the activated cisplatin reversible coordination complex and the coordination nano-micelle and application thereof, the coordination nano-micelle not only can realize cisplatin controlled release regulated by iron ions, but also can reduce ferroptosis of renal tubular cells and related renal cells by chelating the iron ions, so that the renal toxicity of the cisplatin is efficiently inhibited, and the application value is wide.

The present disclosure provides a bioengineered kidney construction method based on organoids and acellular scaffolds, which comprises first injecting pro-vascular stem cells into a kidney acellular scaffold material, and then culturing for several days through fluid circulation perfusion, and then injecting kidney organoids (KIO) into the scaffold material for perfusion culture after the kidney acellular scaffold material is recellularized. The bioengineered kidney obtained by the method of the present disclosure can be used as a graft for replacing kidney function. The present disclosure also provides a kidney organoid culture and expansion method, and the organoids obtained by the method contain not only kidney parenchymal cells such as glomerular cells and renal tubular cells, but also blood vessels and immune cells, which provides a good source of kidney parenchymal cells for the preparation of tissue-engineered kidneys.

The invention provides application of dehydrodiisoeugenol (DHE) to treatment of acute kidney injury by inhibiting ferroptosis, and belongs to the technical field of biological medicine. It is found that DHE can effectively inhibit cell ferroptosis, application of DHE as a ferroptosis inhibitor and application of DHE in preparation of drugs for treating acute kidney injury are provided, and DHE can inhibit renal tubular cell ferroptosis, recover the anti-oxidation defense function and relieve lipid peroxidation and iron deposition. It is proved that DHE is a natural small-molecule inhibitor of ACSL4, ACSL4-mediated ferroptosis can be effectively blocked, powerful protection is provided for cisplatin-induced acute kidney injury, and the DHE becomes a promising treatment candidate drug for cisplatin treatment of patients.

[Problem] The purpose of the present invention is to provide, as each useful agent that contains DHMBA as an active ingredient, a cytoprotective agent against ferroptosis, the cytoprotective agent containing DHMBA as an active ingredient and having a cytoprotective action against ferroptosis by verifying the effect of suppressing ferroptosis cell death of DHMBA using a DN model mouse and a human renal tubular cell HK-2. [Solution] The present invention provides a cell agent against ferroptosis, the cell agent containing 3,5-dihydroxy-4-methoxybenzyl alcohol as an active ingredient and having a cytoprotective action against ferroptosis.

The present invention relates to the fields of nucleic acid drugs and pharmaceutical chemistry, and in particular to a short antisense nucleotide targeting a proximal renal tubule. Provided is an antisense oligonucleotide targeting a proximal tubular cell, or a pharmaceutically acceptable salt thereof. The antisense oligonucleotide has a structure comprising a 5'-wing region, a spacer region, and a 3'-wing region, wherein the 5'-wing region consists of 1-5 nucleotides having a first chemical modification, and the 3'-wing region consists of 1-5 nucleotides having a second chemical modification.

This application provides a wood-based decorative material that has high strength and retains the appearance of wood. The wood-based decorative material comprises wood material and a hydrophobic polymer injected into the wood material, wherein the hydrophobic polymer is in contact with the surface of the cell wall of the tubular cells on the intracellular side when the tubular cells of the wood material have cavities.

The invention discloses a chronic kidney disease glycolysis-immunoregulation analysis method based on multiple omics, which comprises the following steps: acquiring GSE209781 single cell and GSE37171 transcriptome data, and analyzing glycolysis pathway activity and differential genes after preprocessing and cell clustering annotation; molecular subtypes are determined through consensus clustering and immune infiltration assessment; key diagnostic genes such as ETFB and the like are screened in combination with three types of machine learning; molecular docking verifies the binding potential of ETFB and therapeutic drugs. According to the invention, near-end renal tubular cells are positioned as a glycolysis core, an MIF-mediated regulatory network is disclosed, the diagnosis accuracy is improved, a clear treatment target is provided, a standardized analysis system is constructed, and accurate CKD diagnosis and treatment are assisted.

This invention relates to the fields of biomedical engineering and nanomedicine delivery technology, specifically disclosing a homologous membrane nano-targeted drug delivery system for treating acute kidney injury with sepsis. The system includes: preparation of solid silicon spheres; mesoporization and etching; drug loading; preparation of homologous cell membranes; encapsulation and fusion; characterization and quality control. This invention utilizes KTP-modified RBCM vesicles to provide homologous surface proteins / receptors, achieving highly selective recognition and endocytosis of renal tubular cells, significantly improving drug accumulation and bioavailability in diseased kidney tissue, thereby enhancing therapeutic efficacy and reducing systemic exposure. The hollow, mesoporous structure provides high drug loading capacity and controllable release sites. The outer homologous membrane inhibits early leakage under physiological conditions and promotes drug release in inflammatory, acidic microenvironments, or intracellular environments, combining the advantages of sustained release and targeted activation.

The invention relates to application of ginsenoside Ro in preparation of a medicine for preventing and treating kidney stone, and belongs to the technical field of biological medicine. The invention discloses application of ginsenoside in preparation of a medicine for preventing and treating kidney stone. The invention discovers that the ginsenoside Ro has an improvement effect on calcium oxalate (CaOx) crystal deposition, adhesion, renal tubular cell injury and inflammation caused by an ethylene glycol-induced mouse urolithiasis model, and meanwhile, the effect of ZnT1 in renal tubular epithelial cell copper death caused by crystal injury and the copper death resisting effect and mechanism of the ginsenoside Ro are clarified. And a road is laid for novel medicines for treating urolithiasis.

The invention belongs to the technical field of biology, and particularly relates to application of lupeol to preparation of a medicine for preventing or treating renal injury caused by cis-platinum. The invention discovers that the natural compound lupeol has a potential protection effect on the renal injury caused by the cis-platinum for the first time, and in-vivo and in-vitro models prove that the lupeol remarkably relieves renal dysfunction, tissue pathological injury and rising of renal injury markers caused by the cis-platinum, inhibits cell apoptosis and promotes proliferation of renal tubular cells. A transcriptome sequencing result shows that lupeol enhances cell survival and proliferation by activating a PI3K / Akt signal channel, regulates an Nrf2 channel to resist oxidative stress, inhibits nuclear translocation of NF [kappa] B, reduces pro-inflammatory cytokines and inhibits inflammatory response. Results show that lupeol may become a choice for relieving renal toxicity of cis-platinum.

The invention discloses a yang-warming and kidney-tonifying paste patch for preventing diabetes from being converted into diabetic kidney and a preparation method thereof. The traditional Chinese medicine ointment patch is prepared from traditional Chinese medicines such as radix rehmanniae preparata, fructus evodiae, clove, cortex cinnamomi, radix codonopsis, radix puerariae and semen cuscutae, and is prepared by grinding the traditional Chinese medicines into powder, blending the powder into paste and preparing the paste into a cylindrical medicine cake. The traditional Chinese medicine composition acts on the Shenshu acupoint through acupoint application, and traditional Chinese medicine ingredients are used for regulating kidney qi and blood and protecting kidney functions. Clinical tests show that a test group using the application is remarkably superior to a control group in the aspect of improving the traditional Chinese medicine syndromes. The fatty acid binding protein 1 in the early kidney injury marker urine has the effects of regulating lipid metabolism and resisting oxidative stress, can protect renal tubule cells, and has the early kidney injury warning capability, and a test group applying the application has a remarkable effect of reducing the level of the fatty acid binding protein 1. Safety analysis shows that the application is low in adverse reaction occurrence rate and good in safety. The invention provides a traditional Chinese medicine non-drug therapy which has no gastrointestinal burden and is convenient for long-term persistence for preventing and treating the diabetic kidney disease.

This invention discloses the application of a peptide SRD in the preparation of drugs for treating acute kidney injury, belonging to the field of biomedical technology. In an in vitro H2O2-induced oxidative stress injury experiment on renal tubular epithelial cells, this invention found that peptide SRD treatment significantly reduced the apoptosis rate of renal tubular cells damaged by oxidative stress, promoted ATP production, and restored mitochondrial respiratory chain function. In an animal model of ischemia-reperfusion-induced acute kidney injury, mice with acute kidney injury injected via the tail vein showed significantly decreased serum creatinine and blood urea nitrogen levels. Pathological observation revealed a significant reduction in the degree of renal tubular injury, a lower histological score, and a significant downregulation of KIM-1, an indicator of the degree of renal tubular injury. This indicates that the antioxidant peptide SRD can improve mitochondrial function in renal tubular cells, effectively reduce renal tubular cell damage, promote the repair of renal tubular epithelial cells in acute kidney injury (AKI), effectively improve renal function, and has a good therapeutic effect on acute kidney injury.

A composition comprising citrate and carnitine which activates the production of the protein Klotho by renal tubule cells protecting them, thus reducing the oxidative stress conditions thereof, which can be used for the conservation, perfusion and reperfusion of organs for organ transplants is disclosed. Furthermore, the composition in the liquid and dietary / nutraceutical formulation can be used for reducing the nephrotoxicity induced by iodinated contrast means, antibiotics, NSAIDs 10 or agents that induce oxidative stress.